-- 美國股指下跌,而原油期貨價格上漲,原因是旨在促使伊朗重返巴基斯坦參加第二輪談判的高風險外交努力仍在進行中。 那斯達克指數下跌0.5%,收24,344.1點;標普500指數下跌0.3%,收在7,101.5點。此前,由於美國總統川普在上週晚些時候表示,在當前為期兩週的停火協議於週二結束前達成伊朗和平協議的可能性很大,納斯達克綜合指數一度創下歷史新高。道瓊工業指數下跌0.1%,收在49,378.5點。 非必需消費品、通訊服務及科技板塊領跌盤中。能源和原料板塊則是漲幅榜前。 加拿大豐業銀行資本市場經濟學家德里克霍爾特週一在一份報告中表示,新一周開始,市場風險偏好「正在下降」。霍爾特補充說,川普週五似乎「嚴重誇大」了與伊朗達成協議的進展。 根據美國有線電視新聞網(CNN)週一報道,川普表示,與伊朗的停火協議將於「華盛頓時間週三晚間」結束,並補充說,如果在此之前未能達成協議,他「極不可能」延長停火協議。 根據CNN報道,副總統萬斯和美國高級官員預計將於週二啟程前往巴基斯坦伊斯蘭堡,為可能舉行的第二輪與伊朗的會談做準備。一位伊朗高級官員週一告訴路透社,伊朗正在考慮和平談判。此前,伊斯蘭堡方面結束了美國對德黑蘭港口的封鎖,這對於面臨廣泛襲擊威脅的伊朗來說,是重新加入和平進程的一大障礙。 根據彭博社報道,美國總統在周一的電話採訪中表示,與伊朗的第二輪會談定於週二開始。 西德州中質原油期貨上漲5%至每桶88.80美元,布蘭特原油期貨上漲4.8%至每桶95.21美元。 多數美國公債殖利率上升,其中10年期公債殖利率上漲1.8個基點至4.26%,2年期公債殖利率上漲2.5個基點至3.73%,因為原油價格上漲加劇了通膨擔憂。反映出價格上漲的潛在風險,黃金期貨下跌1.2%至每盎司4,822.1美元,白銀期貨下跌2.5%至每盎司79.78美元。 公司方面,受中東地緣政治風險惡化的影響,挪威郵輪公司(NCLH)盤中下跌4.2%,成為標普500指數中表現最差的股票之一。 路透社引述知情人士報道,Meta Platforms (META) 計劃於 5 月 20 日啟動今年的裁員計劃,預計之後還將有更多裁員。這家 Facebook 母公司的股價盤中下跌 2.3%,成為納斯達克表現最差的股票之一。 根據 The Information 引述兩位知情人士報道,Alphabet (GOOG, GOOGL) 旗下的谷歌正在與 Marvell Technology (MRVL) 洽談,共同開發兩款針對人工智慧推理任務優化的新型處理器。 Marvell 的股價盤中上漲 4%,成為納斯達克漲幅最大的股票。
Related Articles
Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%
Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.
ASX Biggest Losers
Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07
Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal
Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.